Haematological malignancies are types of cancers affecting blood, bone marrow and lymph nodes. Broadly speaking, there are three major types of blood cancers: leukaemia, lymphoma and myeloma. Of these, the most common blood cancer types include non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML) and multiple myeloma (MM). In the US, a newly diagnosed blood cancer patient is reported every three minutes, and new cases of blood cancers account for approximately 10% of all new cancer diagnoses. Also, an estimated 1.3 million people in the US are either living with or are in remission from blood cancer. Scientific and technological advances have led to a significant improvement in five-year relative survival rates for blood cancers, having more than doubled for lymphoma and more than quadrupled for myeloma and leukaemia over the last 50 years.
The evolving therapeutic landscape in haematologic malignancies